Skin cancer is one of the most common forms of cancer globally, with millions of cases diagnosed each year. Its prevalence is rising due to factors like increased sun exposure, aging populations, and lifestyle changes. The main types of skin cancer include melanoma, basal cell carcinoma (BCC), and squamous cell carcinoma (SCC), with melanoma being the deadliest. Early detection is crucial for successful treatment, as skin cancer can often be treated effectively if caught early.

However, diagnosing skin cancer can be challenging due to the wide variety of skin conditions and the complexity of distinguishing between benign and malignant growths. Traditional methods of detection, such as visual inspection by dermatologists and biopsies, are time-consuming, subjective, and prone to human error.

AI systems, particularly deep learning and computer vision models, are being increasingly applied to help address these challenges. These AI tools can analyze medical images of skin lesions with high accuracy, sometimes surpassing dermatologists in diagnosing skin cancer. They can quickly identify suspicious moles or growths, enabling earlier and more accurate diagnosis. AI systems can also assist in classifying lesions into categories (benign or malignant) and track changes over time, improving long-term monitoring.

The potential benefits of AI in skin cancer detection include faster diagnosis, reduced workload for healthcare professionals, and improved patient outcomes through early intervention. As AI technology continues to evolve, it may become a key tool in reducing the global burden of skin cancer.

With Cody Simmons, CEO of Dermasensor

Check out other top-rated AI podcasts on FeedSpot:

One of the landmarks in AI was the work on neural networks in the 1970s by Geoffrey Hinton, the "Godfather of AI". This

Longevity and immortality is a key theme in the earliest literature. But what does modern science have to offer to life extension? And in particular, has AI added anything new? With Felix is someone who is actively involved in this field, Dr Cory Goldberg.

Episode 45: AI doctors: how close are they? With Robert Sargsyan, CEO of Docus. Will AI doctors eventually replace human doctors? Are they already doing so? On one hand, people like the human touch of human doctors. On the other hand, human doctors get tired, are limited in terms of the amount of data they can handle and tend to be overstretched. So where are we with the development of AI doctors? Joining me is someone at the cutting edge of this fascinating topic, Robert Sargsyan, CEO of Docus.

Will AI doctors eventually replace human doctors? Are they already doing so? On one hand, people like the human touch of human doctors. On the other hand, medical AI systems could solve many problems in healthcare. So, where are we with the development of AI doctors? Joining me is someone at the cutting edge of this fascinating topic …Robert Sargsyan, CEO of Docus.

Irregular heart rhythms can indicate several potentially fatal health problems, including risk for heart attack and stroke. Here we discuss how AI approaches are helping to transform cardiology, with respect to detection of irregular heart rhythms. With Felix is Stuart Long, CEO of infobionic.ai

Waiting for emergency treatment, when you might already be in shock, can be a very distressing and lonely experience. A big part of the problem might be that you are feeling in the dark about what’s happening and how long you’ll be there. An already stressful situation could feel like an eternity. How can AI systems help here? Two men who have commercialised just such a thing are Aaron Patzer and Dr Justin Schrager, founders of the company Vital.

Some have suggested that the medical profession is a force of resistance in AI adoption, that it is prioritizing the protection of jobs, potentially at the cost of patients

Is there any truth in that?

Or is the medical profession actually protecting

With me is someone who is perfectly placed to discuss this, Dr Jethro Hubbard. He is a GP. And he was also instrumental in the introduction of the BMA policy on healthcare AI integration.

AI has the potential to revolutionize clinical trials in many ways. It could make the development of new treatments faster, safer, cheaper and more personalised. One company in this space is Owkin, a unicorn startup based in Paris. With me is Dr Félix Balazard, Director of

Clinical trials are the cornerstone of the development of new treatments. One can see them as a shining example of the scientific method in practice. One can also see them as phenomenally expensive, with a high rejection

With me to discuss this is Dr Harsha Rajasimha, CEO of Jeeva Clinical Trials.